Athenex, Inc.

FREE EMAIL WATCHDOG

Get free email notifications about news in Athenex, Inc..

The service is free and you can unsubscribe at any time.

General | People (48) | Filings (72) | Investment rounds (10) | Stock | News

Industry: PHARMACEUTICAL PREPARATIONS [2834]

CIK Number: 0001300699
IRS Number: 431985966

Athenex, Inc. is a publicly traded company

Trading symbol: ATNX

Athenex, Inc. is on the market more than 5 years.

News

2017-10-05

Athenex Announces Positive Recommendations from the Drug Safety Monitoring ...
GlobeNewswire (press release)
BUFFALO, N.Y., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, ...

2017-09-25

Athenex, Inc. Announces First Patient Recruitment in Phase III Clinical Trials ...
Nasdaq
25, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the ...
Should You Wait Before Investing In Athenex Inc (ATNX)? - Simply Wall St
Athenex, Inc. (ATNX) Given $27.50 Average Target Price by Brokerages - StockNewsTimes

2017-09-25

BRIEF-Athenex Inc announces first patient recruitment in phase III clinical ...
Reuters
BRIEF-Athenex Inc announces first patient recruitment in phase III clinical trials for KX-01 ointment. Reuters Staff. 1 Min Read.

2017-09-18

Athenex, Inc. Added to Russell 2000® and Russell 3000® Indexes
Nasdaq
18, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that it has been added to ...

2017-09-14

Athenex, Inc. (ATNX) Research Coverage Started at Royal Bank Of Canada
The Ledger Gazette
Athenex logo Analysts at Royal Bank Of Canada began coverage on shares of Athenex, Inc. (NASDAQ:ATNX) in a note issued to investors on Thursday.
Athenex (ATNX) Receiving Somewhat Positive Media Coverage, Accern Reports - StockNewsTimes

2017-09-11

CORRECTING and REPLACING: Athenex, Inc.
GlobeNewswire (press release)
In a release issued earlier today by Athenex, Inc. (Nasdaq:ATNX), please note that the headline and dateline have been updated.

2017-08-31

Athenex Pharmaceutical Division and SunGen Pharma Announce Terbutaline Sulfate ...
GlobeNewswire (press release)
31, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the launch of Terbutaline ...

Athenex, Inc. address

1001 MAIN STREET
SUITE 600
BUFFALO
14203

Former name

Former name of this company was Kinex Pharmaceuticals LLC, date of change: 2004-08-17.

Former name of this company was Kinex Pharmaceuticals, Inc., date of change: 2013-12-23.

Company jurisdiction

DELAWARE

Entity type

Corporation

Earliest known filing

August 2004

Latest known filing

October 2017

Company filings

SEC filings are a great source of information for companies including investments, company events, and all sorts of other information.

Athenex, Inc. has 72 filings. View Athenex, Inc. filings.

Quarterly Reports

Latest company events

Investment Rounds

Athenex, Inc. recieved 10 investments.

People

We have found 48 people related to Athenex, Inc..